Ocugen CSO to Participate in 5th Annual Gene Therapy for Eye Disease Summit

MALVERN, Pa., Sept. 5, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ OCGN), a biotechnology company focused on the discovery, development and commercialization of novel gene and cell therapies and vaccines, today announced that Arun Upadhyay, Ph.D., Chief Scientific Officer and Head of R&D at Ocugen, will be one of the keynote speakers at the 5th Annual^t Annual Conference on Gene Therapy for Ophthalmic Disorders, to be held September 10–12, 2024, in Boston, Massachusetts.

“There is tremendous potential for gene therapy to treat both rare retinal diseases and eye diseases that affect millions of people,” said Dr. Upadhyay. “I look forward to sharing the development and clinical progress of the Ocugen modifier gene therapy platform with my colleagues and learning about the latest advances in this field from industry experts.”

Details of Dr. Upadhyay’s participation are as follows:

Workshop moderator
Topic: Navigating the Regulatory Pathways for Gene Therapies in Ophthalmology
Date:Tuesday, September 10, 2024
Time: 1:00-4:00 PM EST

Presentation
Topic: Advances in Gene Therapy for Ophthalmologic Disorders: Updates to the Ocugen Clinical Program
Date:Thursday, September 12, 2024
Time: 11:30-noon

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing and commercializing novel gene and cell therapies, biologics and vaccines that improve health and provide hope to patients around the world. We impact patients’ lives through bold innovation—forging new scientific paths that leverage our unique intellectual and human capital. Our groundbreaking gene therapy modifier platform has the potential to treat multiple retinal diseases with a single product, and we advance infectious disease research to support public health and orthopedic diseases to address unmet medical needs. Learn more at www.ocugen.com and follow us on X and LinkedIn.

Forecast statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. In some cases, we may use terms such as “anticipates,” “believes,” “potential,” “proposed,” “continues,” “estimates,” “predicts,” “expects,” “plans,” “intends,” “may,” “could,” “will,” “should” or other words that convey the uncertainty of future events or results to identify these forward-looking statements. Such statements are subject to a number of important factors, risks and uncertainties that could cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in our quarterly and annual reports filed with the SEC. Any forward-looking statements we make in this press release speak only as of the date of this press release. Except as required by law, we do not undertake any obligation to update any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
Head of Communications
[email protected]